HCW Biologics announces new paper on treating aging-associated diseases

HCW Biologics published a pivotal scientific paper in Aging Cell entitled, "Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretary phenotype in mice," with Dr. Hing Wong, the Company’s Founder and CEO, as lead and corresponding author. The Company is currently evaluating one of its lead product candidates, HCW9218, a bifunctional immunotherapeutic compound, in patients with chemo-resistant/chemo-refractory advanced pancreatic cancer and solid tumors. In this publication, the Company demonstrates HCW9218 may have much broader therapeutic potential beyond cancer to other age-related diseases and conditions because of its ability to promote cell-mediated mechanisms to reduce senescent cells and alleviate the proinflammatory factors they secrete, known as senescence-associated secretory phenotype factors, as shown in mice. Dr. Wong stated, "We believe that HCW9218 has the potential to redefine the approach for treating aging conditions and age-related diseases. Aged immune systems can often breakdown and stop operating the way they were intended, and this opens the door to problems that diminish healthspan and longevity." He continued, "In many ways, this paper presents our seminal work on aging based on our primary premise that rejuvenating the immune system creates a systemic change that reduces senescence and SASP factors. We have seen that HCW9218 can do both, even under conditions where the stressors of cellular senescence are poorly defined or unknown."